Literature DB >> 24421046

Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against Chagas disease.

Shivali Gupta1, Trevor S Silva, Jessica E Osizugbo, Laura Tucker, Heidi M Spratt, Nisha J Garg.   

Abstract

Chagas disease is endemic in Latin America and an emerging infectious disease in the United States. No effective treatments are available. The TcG1, TcG2, and TcG4 antigens are highly conserved in clinically relevant Trypanosoma cruzi isolates and are recognized by B and T cells in infected hosts. Delivery of these antigens as a DNA prime/protein boost vaccine (TcVac2) elicited lytic antibodies and type 1 CD8(+) T cells that expanded upon challenge infection and provided >90% control of parasite burden and myocarditis in chagasic mice. Here we determined if peripheral blood can be utilized to capture the TcVac2-induced protection from Chagas disease. We evaluated the serum levels of T. cruzi kinetoplast DNA (TckDNA), T. cruzi 18S ribosomal DNA (Tc18SrDNA), and murine mitochondrial DNA (mtDNA) as indicators of parasite persistence and tissue damage and monitored the effect of sera on macrophage phenotype. Circulating TckDNA/Tc18SrDNA and mtDNA were decreased by >3- to 5-fold and 2-fold, respectively, in vaccinated infected mice compared to nonvaccinated infected mice. Macrophages incubated with sera from vaccinated infected mice exhibited M2 surface markers (CD16, CD32, CD200, and CD206), moderate proliferation, a low oxidative/nitrosative burst, and a regulatory/anti-inflammatory cytokine response (interleukin-4 [IL-4] plus IL-10 > tumor necrosis factor alpha [TNF-α]). In comparison, macrophages incubated with sera from nonvaccinated infected mice exhibited M1 surface markers, vigorous proliferation, a substantial oxidative/nitrosative burst, and a proinflammatory cytokine response (TNF-α ≫ IL-4 plus IL-10). Cardiac infiltration of macrophages and TNF-α and oxidant levels were significantly reduced in TcVac2-immunized chagasic mice. We conclude that circulating TcDNA and mtDNA levels and macrophage phenotype mediated by serum constituents reflect in vivo levels of parasite persistence, tissue damage, and inflammatory/anti-inflammatory state and have potential utility in evaluating disease severity and efficacy of vaccines and drug therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24421046      PMCID: PMC3993374          DOI: 10.1128/IAI.01186-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis.

Authors:  M D Higuchi; M M Ries; V D Aiello; L A Benvenuti; P S Gutierrez; G Bellotti; F Pileggi
Journal:  Am J Trop Med Hyg       Date:  1997-05       Impact factor: 2.345

2.  Chagas disease in European countries: the challenge of a surveillance system.

Authors:  L Basile; J M Jansa; Y Carlier; D D Salamanca; A Angheben; A Bartoloni; J Seixas; T Van Gool; C Canavate; M Flores-Chavez; Y Jackson; P L Chiodini; P Albajar-Vinas
Journal:  Euro Surveill       Date:  2011-09-15

Review 3.  TLR-dependent T cell activation in autoimmunity.

Authors:  Kingston H G Mills
Journal:  Nat Rev Immunol       Date:  2011-11-18       Impact factor: 53.106

4.  Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy.

Authors:  Norma Leticia Bautista-López; Carlos A Morillo; Patricio López-Jaramillo; Roberto Quiroz; Carlos Luengas; Sandra Y Silva; Jacques Galipeau; Manoj Mathew Lalu; Richard Schulz
Journal:  Am Heart J       Date:  2013-02-15       Impact factor: 4.749

5.  Tissue-specific oxidative imbalance and mitochondrial dysfunction during Trypanosoma cruzi infection in mice.

Authors:  Jian-Jun Wen; Monisha Dhiman; Elbert B Whorton; Nisha Jain Garg
Journal:  Microbes Infect       Date:  2008-07-16       Impact factor: 2.700

6.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

7.  IL-10 mediates susceptibility to Trypanosoma cruzi infection.

Authors:  S G Reed; C E Brownell; D M Russo; J S Silva; K H Grabstein; P J Morrissey
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

Review 8.  Cytokine production profile of heart-infiltrating T cells in Chagas' disease cardiomyopathy.

Authors:  E Cunha-Neto; L V Rizzo; F Albuquerque; L Abel; L Guilherme; E Bocchi; F Bacal; D Carrara; B Ianni; C Mady; J Kalil
Journal:  Braz J Med Biol Res       Date:  1998-01       Impact factor: 2.590

9.  Role for interleukin-1 beta in Trypanosoma cruzi-induced cardiomyocyte hypertrophy.

Authors:  Christine A Petersen; Barbara A Burleigh
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  [Not Available].

Authors:  Shivali Gupta; Jian-Jun Wen; Nisha Jain Garg
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-06-14
View more
  12 in total

1.  Diet regulates liver autophagy differentially in murine acute Trypanosoma cruzi infection.

Authors:  Kezia Lizardo; Vanessa Almonte; Calvin Law; Janeesh Plakkal Aiyyappan; Min-Hui Cui; Jyothi F Nagajyothi
Journal:  Parasitol Res       Date:  2016-12-16       Impact factor: 2.289

2.  Gene Expression Profiling and Functional Characterization of Macrophages in Response to Circulatory Microparticles Produced during Trypanosoma cruzi Infection and Chagas Disease.

Authors:  Imran H Chowdhury; Sue-Jie Koo; Shivali Gupta; Lisa Yi Liang; Bojlul Bahar; Laura Silla; Julio Nuñez-Burgos; Natalia Barrientos; Maria Paola Zago; Nisha Jain Garg
Journal:  J Innate Immun       Date:  2016-12-01       Impact factor: 7.349

3.  Macrophages Promote Oxidative Metabolism To Drive Nitric Oxide Generation in Response to Trypanosoma cruzi.

Authors:  Sue-Jie Koo; Imran H Chowdhury; Bartosz Szczesny; Xianxiu Wan; Nisha J Garg
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

Review 4.  Experimental Vaccines against Chagas Disease: A Journey through History.

Authors:  Olivia Rodríguez-Morales; Víctor Monteón-Padilla; Silvia C Carrillo-Sánchez; Martha Rios-Castro; Mariana Martínez-Cruz; Alejandro Carabarin-Lima; Minerva Arce-Fonseca
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

5.  P47phox-/- mice are compromised in expansion and activation of CD8+ T cells and susceptible to Trypanosoma cruzi infection.

Authors:  Monisha Dhiman; Nisha Jain Garg
Journal:  PLoS Pathog       Date:  2014-12-04       Impact factor: 6.823

6.  Cancer Stem Cells: Emergent Nature of Tumor Emergency.

Authors:  Yaroslav R Efremov; Anastasia S Proskurina; Ekaterina A Potter; Evgenia V Dolgova; Oksana V Efremova; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Front Genet       Date:  2018-11-16       Impact factor: 4.599

7.  TcG2/TcG4 DNA Vaccine Induces Th1 Immunity Against Acute Trypanosoma cruzi Infection: Adjuvant and Antigenic Effects of Heterologous T. rangeli Booster Immunization.

Authors:  Shivali Gupta; Berenice Salgado-Jiménez; Nandadeva Lokugamage; Juan Carlos Vázquez-Chagoyán; Nisha Jain Garg
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

8.  Pathogenesis of Chronic Chagas Disease: Macrophages, Mitochondria, and Oxidative Stress.

Authors:  Marcos Lopez; Herbert B Tanowitz; Nisha J Garg
Journal:  Curr Clin Microbiol Rep       Date:  2018-01-19

Review 9.  CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development?

Authors:  Fernando Dos Santos Virgilio; Camila Pontes; Mariana Ribeiro Dominguez; Jonatan Ersching; Mauricio Martins Rodrigues; José Ronnie Vasconcelos
Journal:  Mediators Inflamm       Date:  2014-07-01       Impact factor: 4.711

10.  Origin of Monocytes/Macrophages Contributing to Chronic Inflammation in Chagas Disease: SIRT1 Inhibition of FAK-NFκB-Dependent Proliferation and Proinflammatory Activation of Macrophages.

Authors:  Xianxiu Wan; Imran Hussain Chowdhury; Zuliang Jie; Subhadip Choudhuri; Nisha Jain Garg
Journal:  Cells       Date:  2019-12-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.